APP and Alzheimer disease: Thus, at the ages used, APP/PS1 could correlate with the early stage of the disease suggesting PRGF could have a prevention potential, while 5XFAD mice could correlate with late stage AD, suggesting PRGF is not an effective treatment for late stage AD.